Logo image of HROW

HARROW INC (HROW) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:HROW - US4158581094 - Common Stock

41.78 USD
+0.48 (+1.16%)
Last: 11/28/2025, 7:37:06 PM
41.78 USD
0 (0%)
After Hours: 11/28/2025, 7:37:06 PM
Fundamental Rating

5

Taking everything into account, HROW scores 5 out of 10 in our fundamental rating. HROW was compared to 192 industry peers in the Pharmaceuticals industry. HROW has only an average score on both its financial health and profitability. HROW is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

HROW had positive earnings in the past year.
HROW had a positive operating cash flow in the past year.
In the past 5 years HROW always reported negative net income.
In multiple years HROW reported negative operating cash flow during the last 5 years.
HROW Yearly Net Income VS EBIT VS OCF VS FCFHROW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

HROW has a better Return On Assets (-1.37%) than 74.48% of its industry peers.
The Return On Equity of HROW (-10.61%) is better than 73.44% of its industry peers.
Looking at the Return On Invested Capital, with a value of 7.45%, HROW belongs to the top of the industry, outperforming 85.42% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for HROW is significantly below the industry average of 12.71%.
The last Return On Invested Capital (7.45%) for HROW is above the 3 year average (1.25%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -1.37%
ROE -10.61%
ROIC 7.45%
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
HROW Yearly ROA, ROE, ROICHROW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

HROW has a Operating Margin of 11.23%. This is amongst the best in the industry. HROW outperforms 83.33% of its industry peers.
HROW's Operating Margin has improved in the last couple of years.
HROW has a Gross Margin of 74.56%. This is amongst the best in the industry. HROW outperforms 80.21% of its industry peers.
HROW's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 11.23%
PM (TTM) N/A
GM 74.56%
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
HROW Yearly Profit, Operating, Gross MarginsHROW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

4

2. Health

2.1 Basic Checks

HROW has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, HROW has more shares outstanding
The number of shares outstanding for HROW has been increased compared to 5 years ago.
The debt/assets ratio for HROW has been reduced compared to a year ago.
HROW Yearly Shares OutstandingHROW Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
HROW Yearly Total Debt VS Total AssetsHROW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

HROW has an Altman-Z score of 3.62. This indicates that HROW is financially healthy and has little risk of bankruptcy at the moment.
HROW has a better Altman-Z score (3.62) than 70.83% of its industry peers.
HROW has a Debt/Equity ratio of 5.17. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of HROW (5.17) is worse than 80.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.17
Debt/FCF N/A
Altman-Z 3.62
ROIC/WACC0.81
WACC9.24%
HROW Yearly LT Debt VS Equity VS FCFHROW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.72 indicates that HROW has no problem at all paying its short term obligations.
HROW has a Current ratio (2.72) which is comparable to the rest of the industry.
A Quick Ratio of 2.52 indicates that HROW has no problem at all paying its short term obligations.
HROW has a Quick ratio of 2.52. This is comparable to the rest of the industry: HROW outperforms 51.04% of its industry peers.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.52
HROW Yearly Current Assets VS Current LiabilitesHROW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 109.68% over the past year.
HROW shows a strong growth in Revenue. In the last year, the Revenue has grown by 47.83%.
HROW shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.29% yearly.
EPS 1Y (TTM)109.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%283.33%
Revenue 1Y (TTM)47.83%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%45.44%

3.2 Future

HROW is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 72.94% yearly.
HROW is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.80% yearly.
EPS Next Y197.23%
EPS Next 2Y148.51%
EPS Next 3Y112.08%
EPS Next 5Y72.94%
Revenue Next Year44.76%
Revenue Next 2Y42.98%
Revenue Next 3Y41.87%
Revenue Next 5Y34.8%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
HROW Yearly Revenue VS EstimatesHROW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
HROW Yearly EPS VS EstimatesHROW Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 464.22, the valuation of HROW can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of HROW indicates a somewhat cheap valuation: HROW is cheaper than 76.04% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.31, HROW is valued quite expensively.
With a Price/Forward Earnings ratio of 22.74, HROW is valued on the expensive side.
HROW's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. HROW is cheaper than 75.00% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of HROW to the average of the S&P500 Index (36.59), we can say HROW is valued slightly cheaper.
Industry RankSector Rank
PE 464.22
Fwd PE 22.74
HROW Price Earnings VS Forward Price EarningsHROW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300 400

4.2 Price Multiples

77.60% of the companies in the same industry are more expensive than HROW, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 37.22
HROW Per share dataHROW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HROW does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of HROW may justify a higher PE ratio.
A more expensive valuation may be justified as HROW's earnings are expected to grow with 112.08% in the coming years.
PEG (NY)2.35
PEG (5Y)N/A
EPS Next 2Y148.51%
EPS Next 3Y112.08%

More info and screens

0

5. Dividend

5.1 Amount

HROW does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HARROW INC

NASDAQ:HROW (11/28/2025, 7:37:06 PM)

After market: 41.78 0 (0%)

41.78

+0.48 (+1.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)03-16 2026-03-16/amc
Inst Owners57.65%
Inst Owner Change1.26%
Ins Owners15.72%
Ins Owner Change5.45%
Market Cap1.55B
Revenue(TTM)250.04M
Net Income(TTM)-4.99M
Analysts85.71
Price Target72.13 (72.64%)
Short Float %18.23%
Short Ratio7.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)819.91%
Min EPS beat(2)-18.12%
Max EPS beat(2)1657.94%
EPS beat(4)2
Avg EPS beat(4)222.09%
Min EPS beat(4)-970.3%
Max EPS beat(4)1657.94%
EPS beat(8)3
Avg EPS beat(8)30%
EPS beat(12)4
Avg EPS beat(12)-52.89%
EPS beat(16)5
Avg EPS beat(16)-847.87%
Revenue beat(2)0
Avg Revenue beat(2)-5.01%
Min Revenue beat(2)-5.31%
Max Revenue beat(2)-4.71%
Revenue beat(4)1
Avg Revenue beat(4)-5.43%
Min Revenue beat(4)-17.73%
Max Revenue beat(4)6.04%
Revenue beat(8)2
Avg Revenue beat(8)-3.74%
Revenue beat(12)4
Avg Revenue beat(12)-3.32%
Revenue beat(16)7
Avg Revenue beat(16)-1.63%
PT rev (1m)14.11%
PT rev (3m)18.19%
EPS NQ rev (1m)-17.84%
EPS NQ rev (3m)-17.75%
EPS NY rev (1m)0%
EPS NY rev (3m)18.15%
Revenue NQ rev (1m)-5.84%
Revenue NQ rev (3m)-7.61%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.33%
Valuation
Industry RankSector Rank
PE 464.22
Fwd PE 22.74
P/S 6.19
P/FCF N/A
P/OCF 87.56
P/B 32.91
P/tB N/A
EV/EBITDA 37.22
EPS(TTM)0.09
EY0.22%
EPS(NY)1.84
Fwd EY4.4%
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)0.48
OCFY1.14%
SpS6.75
BVpS1.27
TBVpS-3.43
PEG (NY)2.35
PEG (5Y)N/A
Graham Number1.6
Profitability
Industry RankSector Rank
ROA -1.37%
ROE -10.61%
ROCE 9.43%
ROIC 7.45%
ROICexc 9.93%
ROICexgc 45.02%
OM 11.23%
PM (TTM) N/A
GM 74.56%
FCFM N/A
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
ROICexc(3y)2.44%
ROICexc(5y)3.09%
ROICexgc(3y)9.66%
ROICexgc(5y)8.29%
ROCE(3y)1.58%
ROCE(5y)1.69%
ROICexgc growth 3Y16.24%
ROICexgc growth 5YN/A
ROICexc growth 3Y-9.77%
ROICexc growth 5YN/A
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
F-Score7
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 5.17
Debt/FCF N/A
Debt/EBITDA 5.27
Cap/Depr 212.17%
Cap/Sales 15.3%
Interest Coverage 1.18
Cash Conversion 38.33%
Profit Quality N/A
Current Ratio 2.72
Quick Ratio 2.52
Altman-Z 3.62
F-Score7
WACC9.24%
ROIC/WACC0.81
Cap/Depr(3y)560.55%
Cap/Depr(5y)363.77%
Cap/Sales(3y)46.48%
Cap/Sales(5y)28.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)109.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%283.33%
EPS Next Y197.23%
EPS Next 2Y148.51%
EPS Next 3Y112.08%
EPS Next 5Y72.94%
Revenue 1Y (TTM)47.83%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%45.44%
Revenue Next Year44.76%
Revenue Next 2Y42.98%
Revenue Next 3Y41.87%
Revenue Next 5Y34.8%
EBIT growth 1Y427.53%
EBIT growth 3Y69.3%
EBIT growth 5YN/A
EBIT Next Year1336.35%
EBIT Next 3Y239.76%
EBIT Next 5Y132.11%
FCF growth 1Y87.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y306.23%
OCF growth 3YN/A
OCF growth 5YN/A

HARROW INC / HROW FAQ

Can you provide the ChartMill fundamental rating for HARROW INC?

ChartMill assigns a fundamental rating of 5 / 10 to HROW.


What is the valuation status for HROW stock?

ChartMill assigns a valuation rating of 4 / 10 to HARROW INC (HROW). This can be considered as Fairly Valued.


Can you provide the profitability details for HARROW INC?

HARROW INC (HROW) has a profitability rating of 6 / 10.


What are the PE and PB ratios of HARROW INC (HROW) stock?

The Price/Earnings (PE) ratio for HARROW INC (HROW) is 464.22 and the Price/Book (PB) ratio is 32.91.


What is the financial health of HARROW INC (HROW) stock?

The financial health rating of HARROW INC (HROW) is 4 / 10.